Wegovy Faces New Competition and Patent Challenges as Novo Nordisk Seeks Growth Beyond Blockbuster Weight Loss Drug

# Wegovy's New Chapter: Competition, Patents, and the Race for What's Next **Episode Description:** Wegovy built the modern weight-loss drug market—but can it stay on top? In this episode, we break down Novo Nordisk's pivotal moment as investors question the company's strategy beyond its blockbuster GLP-1 drugs, Wegovy and Ozempic. We cover the London investor meeting that sent Novo Nordisk shares tumbling up to 9%, the looming 2032 patent cliff for semaglutide, and why Eli Lilly's Zepbound is projected to outsell Wegovy by roughly $7 billion this year. We dive into the rise of oral Wegovy—now used by 1.5 million patients—and what its cash-pay-heavy adoption reveals about affordability and access in obesity treatment. You'll also hear about upcoming Wegovy data drops at the EASD conference in Milan, including real-world evidence from the Octane study, new findings on liver health (MASH), a higher 7.2mg dose, and early signals from the experimental drug CagriSema. Plus, we unpack a recent U.S. appeals court ruling on semaglutide shortages and what it means for compounding pharmacies and medical spas. Whether you're a patient, investor, healthcare provider, or just tracking the GLP-1 boom, this episode separates confirmed clinical and business developments from hype—so you know what's actually changing in the obesity drug landscape. **Topics covered:** Wegovy vs. Zepbound, Novo Nordisk earnings and strategy, semaglutide patent expiration, oral Wegovy pill rollout, CagriSema trial data, EASD Milan conference, Wegovy MASH liver studies, semaglutide shortage ruling, GLP-1 drug market competition. **Keywords:** Wegovy, Novo Nordisk, Ozemp Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai